Amy Case
CMO Pulmonary Fibrosis Foundation
Dr. Amy Hajari Case is Chief Medical Officer of the Pulmonary Fibrosis Foundation and a leading voice in patient-centred care for interstitial lung disease. She serves as Director of the Interstitial Lung Disease Program and Pulmonary and Critical Care Research at Piedmont Healthcare, where she leads advanced lung disease initiatives and is principal investigator on multiple pulmonary fibrosis clinical trials.
Deeply committed to patient advocacy, Dr. Case has built nationally recognised ILD programmes, leads patient support groups, and drives education and awareness efforts across the pulmonary fibrosis community. A fellow of the American College of Chest Physicians and member of the American Thoracic Society, she is dedicated to expanding access to innovative therapies while improving outcomes and quality of life for patients living with pulmonary fibrosis.
Seminars
This session will explore how patient organizations, philanthropic foundations, and non-traditional stakeholders are influencing the future of IPF, PPF, and ILD drug development, from translational research funding and biomarker development to trial design, regulatory engagement, and patient access.
- Explore how advocacy groups and research-focused foundations are shaping priorities across the IPF and PPF development landscape
- Discuss the growing role of philanthropic and non-profit organizations in funding translational research, biomarker development, and early-stage therapeutic innovation
- Examine opportunities to accelerate therapy development through collaboration across academia, foundations, biotech, pharma, and patient communities
- Identify practical approaches for building long-term partnerships that extend beyond recruitment into sustained scientific and strategic collaboration
- Assess how patient-informed initiatives are influencing endpoint development, earlier diagnosis strategies, and future treatment paradigms
As IPF drug development grows more complex, it’s important to pause and reflect on why we do what we do. This session brings the conversation back to what matters most, grounding scientific and clinical discussions in real patient impact, and ensuring progress across the field remains both meaningful and measurable.
- Comparing commonly used IPF patient-reported outcome measures, including ERS-IPF, K-BILD, cough-specific instruments, and Living with IPF to understand their strengths, limitations, and clinical relevance
- Exploring why PRO use varies across trials, including regulatory expectations, endpoint selection, and differences in therapeutic mechanisms
- Discussing whether the field should move toward standardized PRO frameworks to better capture symptoms such as cough, breathlessness, fatigue, and overall quality of life
